Divergent routes to oral cancer

被引:67
作者
Hunter, Keith D.
Thurlow, Johanna K.
Fleming, Janis
Drake, Paul J. H.
Vass, J. Keith
Kalna, Gabriela
Higham, Des J.
Herzyk, Pawel
MacDonald, D. Gordon
Parkinson, E. Ken
Harrison, Paul R.
机构
[1] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland
[2] Glasgow Dent Hosp & Sch, Glasgow, Lanark, Scotland
[3] Univ Glasgow, Sir Henry Wellcome Funct Genom Facil, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland
[4] Univ Strathclyde, Dept Math, Glasgow, Lanark, Scotland
基金
英国工程与自然科学研究理事会;
关键词
D O I
10.1158/0008-5472.CAN-06-0186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Most head and neck squamous cell carcinoma (HNSCC) patients present with late-stage cancers, which are difficult to treat. Therefore, early diagnosis of high-risk premalignant lesions and incipient cancers is important. HNSCC is currently perceived as a single progression mechanism, resulting in immortal invasive cancers. However, we have found that similar to 40% of primary oral SCCs are mortal in culture, and these have a better prognosis. About 60% of oral premalignancies (dysplasias) are also mortal. The mortal and immortal tumors are generated in vivo as judged by p53 mutations and loss of p16(INK4A) expression being found only in the original tumors from which the immortal cultures were derived. To investigate the relationships of dysplasias to SCCs, we did microarray analysis of primary cultures of 4 normal oral mucosa biopsies, 19 dysplasias, and 16 SCCs. Spectral clustering using the singular value decomposition and other bioinformatic techniques showed that development of mortal and immortal SCCs involves distinct transcriptional changes. Both SCC classes share most of the transcriptional changes found in their respective dysplasias but have additional changes. Moreover, high-risk dysplasias that subsequently progress to SCCs more closely resemble SCCs than nonprogressing dysplasias. This indicates for the first time that there are divergent mortal and immortal pathways for oral SCC development via intermediate dysplasias. We believe that this new information may lead to new ways of classifying HNSCC in relation to prognosis.
引用
收藏
页码:7405 / 7413
页数:9
相关论文
共 50 条
[1]  
Baek JH, 2003, INT J MOL MED, V12, P319
[2]   Cancer and the chemokine network [J].
Balkwill, F .
NATURE REVIEWS CANCER, 2004, 4 (07) :540-550
[3]   DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis [J].
Bartkova, J ;
Horejsi, Z ;
Koed, K ;
Krämer, A ;
Tort, F ;
Zieger, K ;
Guldberg, P ;
Sehested, M ;
Nesland, JM ;
Lukas, C ;
Orntoft, T ;
Lukas, J ;
Bartek, J .
NATURE, 2005, 434 (7035) :864-870
[4]  
Bedi GC, 1996, CANCER RES, V56, P2484
[5]   Hitting their targets: an emerging picture of E2F and cell cycle control [J].
Blais, A ;
Dynlacht, BD .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2004, 14 (05) :527-532
[6]   TP53 and head and neck neoplasms [J].
Blons, H ;
Laurent-Puig, P .
HUMAN MUTATION, 2003, 21 (03) :252-257
[7]   The emerging roles of human tissue kallikreins in cancer [J].
Borgoño, CA ;
Diamandis, EP .
NATURE REVIEWS CANCER, 2004, 4 (11) :876-890
[8]  
Braakhuis BJM, 2003, CANCER RES, V63, P1727
[9]   Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments [J].
Breitling, R ;
Armengaud, P ;
Amtmann, A ;
Herzyk, P .
FEBS LETTERS, 2004, 573 (1-3) :83-92
[10]   Iterative Group Analysis (iGA): A simple tool to enhance sensitivity and facilitate interpretation of microarray experiments [J].
Breitling, R ;
Amtmann, A ;
Herzyk, P .
BMC BIOINFORMATICS, 2004, 5 (1)